---
schema_version: "secwatch.filing_event.v1"
accession: "0001551986-23-000047"
form_type: "8-K"
ticker: null
cik: "0001551986"
company_name: "9 METERS BIOPHARMA, INC."
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T11:39:49.807802+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 9 Meters CEO resigns; interim CEO appointed; vurolenatide Phase 2 trial planned

## Summary
- CEO John Temperato resigns effective May 26, 2023; Bethany Sensenig (CFO) named interim CEO.
- Separation agreement includes 12 months base salary, pro-rated 2023 bonus, and 12 months equity vesting extension.
- Company revises vurolenatide plan: additional Phase 2 trial for SBS instead of Phase 3, subject to funding availability.
- Company continues to assess strategic alternatives; trial timing depends on securing funding.

## SEC filing metadata
- accession: 0001551986-23-000047
- form_type: 8-K
- cik: 0001551986
- company_name: 9 METERS BIOPHARMA, INC.
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/0001551986-23-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/nmtr-20230526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551986-23-000047
- JSON: https://secwatch.observer/filing/0001551986-23-000047.json
- Plain text: https://secwatch.observer/filing/0001551986-23-000047.txt

## Key facts
- Executive change
  John Temperato resigned as Chief Executive Officer at 9 METERS BIOPHARMA, INC..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: John Temperato, the Chief Executive Officer (the “CEO”) and a Class II director on the Board of Directors (the “Board”) of 9 Meters Biopharma, Inc. (the “Company”) resigned from his role as CEO and director of the Company, effective at the close of business on May 26, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/0001551986-23-000047-index.htm
- Executive change
  Bethany Sensenig was appointed as Interim Chief Executive Officer at 9 METERS BIOPHARMA, INC..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: The Board appointed Bethany Sensenig, Chief Financial Officer of the Company, to serve as Interim Chief Executive Officer, and principal executive officer for SEC purposes, of the Company, in addition to her current responsibilities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/0001551986-23-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.